Last Update 10 Apr 26

IPN: Oncology Pipeline Progress And Safety Setbacks Will Shape Balanced Future Outlook

Analysts have adjusted the Ipsen price target to €151.94, with recent research pointing to updated revenue growth and profit margin assumptions, as well as fresh Street targets around €160 and €170 as key drivers of the new view.

Analyst Commentary

Bullish Takeaways

Bullish analysts are pointing to higher price targets around €160 and €170, which reflects confidence in Ipsen’s ability to execute on its current pipeline and financial framework despite recent product-specific issues.
The price target increase of €15 at JPMorgan suggests that some large houses see room for upside in the shares based on updated revenue and margin assumptions, even after factoring in recent events around Tazverik.
The move from an Underperform to Neutral stance at one firm with a €160 target indicates that previously cautious analysts now see Ipsen as more fairly aligned with their expectations, which can help support valuation stability.
Deutsche Bank’s €170 target, together with other Street figures, helps anchor the current consensus view around Ipsen at a level that implies ongoing confidence in management’s ability to deliver on its core business.

Bearish Takeaways

Bearish analysts are focused on the voluntary withdrawal of tazemetostat and the discontinuation of related clinical trials, which removes a potential contributor from Ipsen’s future revenue mix and raises questions around execution risk in that area.
The product recall decision linked to emerging safety data in the SYMPHONY-1 trial may weigh on sentiment, as investors reassess how Ipsen manages clinical and regulatory risk in its portfolio.
Comments from other sector analysts highlighting secondary malignancy concerns in the Tazverik trial underline that safety events can influence how regulators look at similar mechanisms, which may add a layer of uncertainty for Ipsen in related indications.
While some external analysts argue that the market reaction in peer names is an overreaction, the episode underscores how quickly sentiment can shift when safety data surfaces, and that can translate into a more cautious stance on Ipsen’s risk profile and valuation multiples for some investors.

What's in the News

Ipsen is voluntarily withdrawing Tazverik in all indications across its markets after emerging Phase Ib/III SYMPHONY-1 data suggested secondary hematologic malignancy risks may outweigh potential benefits in combination treatment for follicular lymphoma. The company is discontinuing all related clinical trials and expanded access programs and is working with the U.S. FDA on next steps (Key Developments).
The company announced new preclinical data at the AACR congress for early development oncology programs, including T cell activator IPN01203 and antibody drug conjugate IPN60300. Both are described as first in class candidates in ongoing Phase I/II studies targeting solid tumors with significant unmet needs (Key Developments).
The U.S. FDA granted Breakthrough Therapy Designation for IPN60340 in combination with venetoclax and azacitidine for first line unfit acute myeloid leukemia, following Phase I/II EVICTION trial data that showed high response rates and a tolerability profile that supports further development discussions with regulators (Key Developments).
Ipsen announced an annual dividend of €1.6000 per share, scheduled to be paid on 5 June 2026, with an ex date of 3 June 2026 and a record date of 4 June 2026 (Key Developments).
An arbitral tribunal confirmed the termination of a 2014 neuromodulator research and development partnership with Galderma that covered early stage neuromodulator projects for aesthetic indications, while existing commercialization arrangements for products such as Dysport/Azzalure remain in place according to Galderma (Key Developments).

Valuation Changes

Fair Value: The €151.94 fair value estimate is unchanged, indicating that the latest inputs leave the central valuation view intact.
Discount Rate: The discount rate remains at 6.29%, so the required return used to assess Ipsen’s shares is stable.
Revenue Growth: Revenue growth assumptions move slightly higher, from 5.35% to 5.46%, reflecting a modestly stronger top-line profile in the model.
Net Profit Margin: Net profit margin assumptions edge down from 19.66% to 19.64%, a very small adjustment that keeps earnings efficiency broadly similar.
Future P/E: The future P/E multiple is adjusted marginally lower, from 16.56x to 16.53x, a tiny change that leaves the overall valuation framework largely consistent.

5 views

Key Takeaways

Expanding specialty drug launches and market share gains, especially in rare diseases and neuroscience, are driving geographic diversification and sustainable higher margins.
A strong pipeline, upcoming regulatory catalysts, and financial flexibility position the company for continued growth through innovation, partnerships, and broader market reach.
Heavy reliance on a few key products and late-stage pipeline success exposes Ipsen to risks from generic competition, loss of exclusivity, and heightened commercial and pricing pressures.

Catalysts

About Ipsen

Operates as a biopharmaceutical company worldwide.What are the underlying business or industry changes driving this perspective?

Strong initial launches and accelerating adoption of new specialty drugs like Iqirvo and Bylvay in rare liver diseases-especially as major reimbursement and regulatory approvals expand access in the US and Europe, with upcoming launches in additional large European countries, directly support revenue growth and geographic diversification.
Growing product momentum and market share gains for Dysport in neuroscience (therapeutics and aesthetics), combined with proven long-term demand drivers from an aging global population and increasing healthcare spending, underpin expectations for sustainable medium-to-long-term revenue streams and higher net margins.
Recent EU approval and upcoming market expansion of Cabometyx in neuroendocrine tumors, and further lifecycle management efforts across key brands, will broaden indications and increase patient reach, enabling top-line growth and supporting profit margin stability.
Anticipated late-stage pipeline catalysts in 2025–2026 across all three therapeutic areas, including pivotal readouts and further regulatory submissions, improve visibility on new product revenue streams, reducing future earnings risk from maturing assets.
Significant available cash and financial flexibility (€3B firepower, net cash balance) position the company to accelerate external innovation via targeted M&A or licensing, strengthening both pipeline depth and long-term earnings growth potential.

Ipsen Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Ipsen's revenue will grow by 5.5% annually over the next 3 years.
Analysts assume that profit margins will increase from 11.3% today to 19.6% in 3 years time.
Analysts expect earnings to reach €904.9 million (and earnings per share of €11.2) by about April 2029, up from €443.5 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €1.2 billion in earnings, and the most bearish expecting €736.8 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.6x on those 2029 earnings, down from 30.1x today. This future PE is lower than the current PE for the GB Pharmaceuticals industry at 19.8x.
Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.29%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The anticipated increase in generic competition for Somatuline-currently a key revenue driver-poses a significant risk, as sustained supply issues with generics may eventually be resolved, which could result in accelerated erosion of both revenues and profit margins as exclusivity wanes.
Ipsen's portfolio demonstrates high revenue concentration in a small number of leading products across oncology, rare disease, and neuroscience, exposing the company to the risk that patent expirations, loss of market exclusivity, or competitive product launches could create sharp and sustained declines in top-line revenue and net earnings.
The company's future growth strategy relies heavily on the successful execution and commercialization of its late-stage pipeline; delays, failed trials, or regulatory setbacks-especially for new indications of Iqirvo, Bylvay, or the long-acting neurotoxin-could result in revenue shortfalls and threaten long-term earnings growth.
Heightened commercial investment, increased R&D expenditure, and integration risks related to external innovation (i.e., acquisitions or partnerships) could pressure net margins if acquired assets underperform, trial costs overrun, or anticipated revenue synergies fail to materialize.
Intensifying industry-wide pricing pressures, payer negotiations (notably in Europe), and global currency headwinds could constrain long-term revenue growth and profitability, as evident from ongoing pricing pressure on Decapeptyl and the explicit guidance assumptions around negative currency impact and profitability headwinds.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €151.94 for Ipsen based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €175.0, and the most bearish reporting a price target of just €117.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €4.6 billion, earnings will come to €904.9 million, and it would be trading on a PE ratio of 16.6x, assuming you use a discount rate of 6.3%.
Given the current share price of €162.7, the analyst price target of €151.94 is 7.1% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Ipsen?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Global Approvals And Guidance Will Drive Expanded Patient Access Worldwide